Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTBP2 | P56545 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29635163 | 0.90 | CTBP2 (0.61) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL7073775 | 0.90 | CTBP2 (0.61) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL5180962 | 0.85 | CTBP2 (0.53) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL11181344 | 0.85 | CTBP2 (0.60) | CTBP2POLBL3MBTL1NPC1CASP3 | |
| SCHEMBL25689281 | 0.83 | L3MBTL1 (0.57) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL12106782 | 0.83 | CTBP2 (0.54) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL3016501 | 0.83 | CTBP2 (0.54) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL12106784 | 0.83 | CTBP2 (0.54) | CTBP2POLBL3MBTL1NPC1TAAR1 | |
| SCHEMBL12164760 | 0.82 | BCL2 (0.46) | L3MBTL1ALDH1A1HPGDTDP1 | |
| SCHEMBL1463377 | 0.82 | CTBP2 (0.50) | CTBP2POLBL3MBTL1NPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929400-B | Nickel catalyst system, high-performance polybutadiene and preparation method thereof | 北京化工大学 | 2023-03-14 | — | — | CN | claimed |
| CN-108929400-A | A kind of nickel catalyst system, high-performance polybutadiene and preparation method thereof | 北京化工大学 | 2018-12-04 | — | — | CN | claimed |
| CN-102300550-A | Perfume systems | — | 2011-12-28 | — | — | CN | claimed |
| CN-120136646-A | Method for synthesizing benzyl alkyl ketone compound by visible light catalysis | 中国科学院化学研究所 | 2025-06-13 | — | — | CN | disclosed |
| EP-4271696-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| WO-2022147214-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-109134868-A | A kind of graft copolymer and graft copolymer/argentum nano composite material and preparation method thereof | 北京引发科技有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-108929400-A | A kind of nickel catalyst system, high-performance polybutadiene and preparation method thereof | 北京化工大学 | 2018-12-04 | — | — | CN | disclosed |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2018-06-28 | — | — | US | disclosed |
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012171337-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| EP-2362765-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010065446-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2010-04-29 | — | — | US | disclosed |
| WO-2007135131-A9 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA NV (BE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2007135131-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | WO | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | CTBP2 2897/4885POLB 2552/4885L3MBTL1 2295/4885 |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | CTBP2 4164/4885POLB 4789/4885L3MBTL1 4598/4885 |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | XBP1, DNAJC10, HSPA5 | CTBP2 1810/4885POLB 1895/4885L3MBTL1 341/4885 |
| US-20100105694-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | CTBP2 4788/4885POLB 2060/4885L3MBTL1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.